APL-2301

Synonym(s): MET-102  |  ASN-1733

Class: Membrane-active agent

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Active against Staphylococcus aureus, Escherichia coli, and other NDM-producing strains; disrupts integrity of cell membrane and inhibits NDM
Description:	Synthetic compound derived from nitroxoline (5-nitro-8-hydroxyquinoline) scaffold; shows synergistic effect with meropenem against NDM-1 producing strains; cytotoxic (IC50) and haemolytic activity only at concentrations >12xMIC50
Institute where first reported:	Asieris Pharmaceuticals
Year first mentioned:	2024
Highest developmental phase:	Phase 1 (to begin in Australia in 2024)
Development status:	Active as of 2024

Chemical structure(s):
Canonical SMILES:	C1=CN=C2C(=C1)C(=C(C(=C2O)[N+](=O)[O-])Br)Cl
Isomeric SMILES:	C1=CC2=C(C(=C(C(=C2Cl)Br)[N+](=O)[O-])O)N=C1
InChI:	InChI=1S/C9H4BrClN2O3/c10-5-6(11)4-2-1-3-12-7(4)9(14)8(5)13(15)16/h1-3,14H
InChI Key:	BZGYNSYRIWILNU-UHFFFAOYSA-N

External links:
Main Source:	https://www.tandfonline.com/doi/full/10.1080/22221751.2023.2294854